Month: July 2022

ORYZON Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop Iadademstat in Different Cancers

Oryzon and NCI will collaborate to assess the safety and efficacy of iadademstat in oncology patients with different hematological and...

Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)

CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation...

California Air Resources Board (CARB) Recent Amendments to the Airborne Toxic Control Measure for Reefer Transportation Units Favors Reflect Scientific’s Cryogenic Clean Air Reefer’s

Humacyte Announces Presentation of Preclinical Data on the HAV™ in Coronary Artery Bypass Grafting at the Basic Cardiovascular Sciences Scientific Sessions

DURHAM, N.C., July 19, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable...

Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease

NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company...

error: Content is protected !!